Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA
KEYTRUDA or pembrolizumab is Merck’s anti-PD-1 therapy, used to treat patients with high-risk early-stage triple-negative breast cancer. Credit: Angiola Harry/Unsplash.
KEYTRUDA or pembrolizumab is Merck’s anti-PD-1 therapy, used to treat patients with high-risk early-stage triple-negative breast cancer. Credit: Angiola Harry/Unsplash.